Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Notes Payables (2019 - 2025)

Historic Notes Payables for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $359300.0.

  • Bioadaptives' Notes Payables rose 101945.41% to $359300.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $359300.0, marking a year-over-year increase of 101945.41%. This contributed to the annual value of $311000.0 for FY2024, which is 331.35% down from last year.
  • Per Bioadaptives' latest filing, its Notes Payables stood at $359300.0 for Q3 2025, which was up 101945.41% from $311000.0 recorded in Q2 2025.
  • Over the past 5 years, Bioadaptives' Notes Payables peaked at $479284.0 during Q2 2021, and registered a low of $32096.0 during Q3 2024.
  • Over the past 5 years, Bioadaptives' median Notes Payables value was $347336.0 (recorded in 2023), while the average stood at $349143.6.
  • Per our database at Business Quant, Bioadaptives' Notes Payables plummeted by 9014.47% in 2024 and then soared by 101945.41% in 2025.
  • Quarter analysis of 5 years shows Bioadaptives' Notes Payables stood at $403117.0 in 2021, then fell by 5.29% to $381793.0 in 2022, then dropped by 15.75% to $321658.0 in 2023, then fell by 3.31% to $311000.0 in 2024, then grew by 15.53% to $359300.0 in 2025.
  • Its last three reported values are $359300.0 in Q3 2025, $311000.0 for Q2 2025, and $311000.0 during Q1 2025.